Callan Family Office’s MetLife MET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11M Sell
129,710
-802
-0.6% -$64.7K 0.21% 87
2026
Q1
$9.23M Sell
130,512
-2,425
-2% -$182K 0.21% 89
2025
Q4
$10.5M Buy
132,937
+2,333
+2% +$185K 0.23% 86
2025
Q3
$10.8M Sell
130,604
-10,542
-7% -$830K 0.34% 55
2025
Q2
$11.4M Buy
141,146
+97,391
+223% +$7.52M 0.36% 53
2025
Q1
$3.51M Buy
43,755
+4,485
+11% +$373K 0.26% 84
2024
Q4
$3.22M Buy
+39,270
New +$3.27M 0.2% 97
2023
Q2
Sell
-14,542
Closed -$843K 140
2023
Q1
$843K Buy
+14,542
New +$981K 0.2% 72

Other funds holding MET

Callan Family Office's MET Position: Q2 2026 in Review

Callan Family Office reduced its MetLife (MET) stake by 0.61% in Q2 2026, selling an estimated $64.7K and leaving 129,710 shares worth $11M. The position accounts for 0.21% of the portfolio, ranked #87.

Callan Family Office first reported a position in MET in Q1 2023 and has held it in 8 quarters since. The position peaked at $11.4M in Q2 2025. 1,442 funds tracked by Wall St. Rank hold MET as of Q2 2026.

  • Callan Family Office held 129,710 shares of MetLife worth $11M as of Q2 2026.
  • Callan Family Office sold 802 MetLife shares in Q2 2026, an estimated $64.7K.
  • MetLife made up 0.21% of Callan Family Office's portfolio in Q2 2026, its #87 holding.
  • Callan Family Office first reported a position in MetLife in Q1 2023 and has held it in 8 quarters since.
  • Callan Family Office's MetLife position peaked at $11.4M in Q2 2025.
  • 1,442 funds tracked by Wall St. Rank held MetLife as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.